CAR-T cancer

Oncology

ASCO 2025 interview with Dr Jason Westin

Breaking barriers to CAR T-cell therapy: The vision for expa...

Live from ASCO 2025: Prof. Dr Jason Westin discusses CAR-T Vision, patient access, and the push to expand therapy reach in rare blood cancers.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FD...

Johnson & Johnson’s Janssen unit has filed a rolling submission for its multiple myeloma CAR-T ciltacabtagene autoleucel (cilta-cel) to the FDA, in hot pursuit of Bristol-Myers Squibb’s

Market Access

pharmaphorum podcast bluebird bio Nicola Redfern

Gene therapy and market access: the pharmaphorum podcast

For episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio in the UK.

Views & Analysis

How the NHS got ahead of the curve with CAR-T

The UK’s pharma industry has welcomed the NHS’ fast adoption of the latest CAR-T cancer therapies.

Views & Analysis

Ahead of the curve

Pharma often criticises the NHS for failing to adopt the latest therapies, arguing that NICE’s technology appraisals can drag on and that hospitals often fail to provide the recommended therapies a

News

Scotland's TC BioPharm joins bluebird to develop next-gen CA...

US cancer biotech bluebird bio has joined with TC BioPharm in a collaboration focused on gamma delta CAR-T cells.